PTO judge says she is ‘intrigued’ by request for patients to be involved in patent discussions and examiner training. Patients advocated for a seat at the table during USPTO-FDA’s ‘listening session’ on initiatives to promote greater access to medicines.
Patient groups may get a chance to interact with patent examiners and discuss the current state of art in disease treatments as part of the US Patent and Trademark Office’s efforts to promote greater access to medicines.
At a 19 January “listening session” hosted by the USPTO and US Food and Drug Administration, patient advocates repeatedly called on the patent office to give them a
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.
The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.
